[8] Lebowitz PF, Eng-Wong J, Swain SM, et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 2004;10:6764-9.
[9] Tripathy D, Moisa C, Glück S. An open-label study of capecitabine and docetaxel as neoadjuvant treatment for patients with recently diagnosed HER2-negative breast cancer plus trastuzumab for HER2-positive breast cancer. Eur J Cancer Suppl 2007;5:223 [Abst 2129].
[10] Rastogi, et al Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 B-27 J Clin Oncol. 2008 Feb 10;26(5):775-85
[11] Kamanger F et al Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137 - 2150
Para más información, póngase en contacto con: Donna Edwards, Axon Communications, dedwards@axon-com.com, +44-(0)208-439-9446
